KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Receivables - Net: 2017-2024

Historic Receivables - Net for Moderna (MRNA) over the last 8 years, with Dec 2024 value amounting to $698.0 million.

  • Moderna's Receivables - Net fell 25.92% to $2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year decrease of 25.92%. This contributed to the annual value of $698.0 million for FY2024, which is 55.93% down from last year.
  • According to the latest figures from FY2024, Moderna's Receivables - Net is $698.0 million, which was down 55.93% from $1.6 billion recorded in FY2023.
  • In the past 5 years, Moderna's Receivables - Net registered a high of $3.2 billion during FY2021, and its lowest value of $698.0 million during FY2024.
  • Moreover, its 3-year median value for Receivables - Net was $1.4 billion (2022), whereas its average is $1.2 billion.
  • Its Receivables - Net has fluctuated over the past 5 years, first surged by 25,807.99% in 2020, then slumped by 56.38% in 2022.
  • Moderna's Receivables - Net (Yearly) stood at $1.4 billion in 2020, then skyrocketed by 128.25% to $3.2 billion in 2021, then slumped by 56.38% to $1.4 billion in 2022, then climbed by 14.37% to $1.6 billion in 2023, then slumped by 55.93% to $698.0 million in 2024.